Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Visceral Leishmaniasis Market Expected To Grow In Terms Of Size?

The market size for visceral leishmaniasis has experienced a robust growth over the past few years. Projected to inflate from $1 billion in 2024 to $1.06 billion in 2025, it is poised to grow at a compound annual growth rate (CAGR) of 5.7%. Reasons for this expansion during the historical duration include an escalating disease occurrence, an upsurge in government financing, the market entry of amphotericin B, the creation of miltefosine, intensifying enlightenment campaigns, better access to healthcare in endemic areas, and the establishment of collaborations between the public and private sector.

In the upcoming years, there are expectations for robust expansion in the visceral leishmaniasis market, with projected growth to $1.32 billion by 2029 at a CAGR of 5.7%. This surge during the forecasted period is attributable to factors such as escalating investment in the creation of vaccines, increased global disease tracking initiatives, a rise in public-private partnerships, improved finances for overlooked tropical diseases, and the advent of gene-focused therapies. Some of the major advancements expected to trend during this period consist of gene editing via CRISPR, drug discovery powered by AI, drug delivery augmented by nanotechnology, next-level sequencing for parasite scrutiny, wearable biosensors for preliminary detection, blockchain technology in healthcare supply chain management, diagnosis tools based on smartphone technology and 3D bioprinting for tailoring treatment research.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp

What Market Forces Are Contributing To The Growth Of The Visceral Leishmaniasis Market?

The escalating rates of malnutrition are projected to stimulate the progression of the visceral leishmaniasis market. Malnutrition, an illness resulting from insufficient or disproportionate nutrient consumption vital for the body’s optimal operation, is on the rise due to food insecurity. Limited access to wholesome food leads to a lack of nourishment and deficiencies in essential micronutrients, thereby undermining the immune system. The impact of malnutrition on immune functionality significantly increases susceptibility to infections, including visceral leishmaniasis. Nutrient deficits can hamper the body’s defensive capacities, elevating the likelihood of intense illnesses and associated complications. For instance, the Food and Agriculture Organization, a specialized Italian agency of the United Nations, reported in July 2024 that the number of malnourished individuals had escalated to 723.8 million in 2022, a significant increase from 708.7 million in 2021. Thus, the surge in malnutrition is a major factor propelling the expansion of the visceral leishmaniasis market.

How Is The Visceral Leishmaniasis Market Segmented Across Key Categories?

The visceral leishmaniasismarket covered in this report is segmented –

1) By Treatment: Antiparasitic; Antifungal; Other Treatments

2) By Diagnosis Method: Serological Tests; Molecular Tests; Microscopy; Culture Methods

3) By Route Of Administration: Oral; Injectable; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Subsegments:

1) By Antiparasitic: Pentavalent Antimonials; Miltefosine; Paromomycin; Sitamaquine; Combination Therapy

2) By Antifungal: Amphotericin B; Liposomal Amphotericin B (AmBisome); Azoles; Echinocandins; Polyenes

3) By Other Treatments: Immunotherapy; Monoclonal Antibodies; Vaccine-Based Approaches; Photodynamic Therapy; Gene Therapy

What Key Trends Are Driving Growth In The Visceral Leishmaniasis Market?

Leading businesses within the visceral leishmaniasis market are working on cutting-edge improvements in therapeutic approaches, like the creation of antiparasitic drugs, to boost effectiveness and expand access for patients, predominantly in areas where the disease is widespread. These drugs are specifically formulated to combat parasitic infections by targeting the life processes of the parasite and impeding its growth, reproduction, and survival within the host body. For example, Zydus Lifesciences Limited, a pharmaceutical organization based in India, obtained prequalification approval from the World Health Organization (WHO) in February 2024. This authorization was for its active pharmaceutical ingredient (API) and formulation, miltefosine, used to treat leishmaniasis or kala-azar. This oral antiparasitic medication functions by disrupting the cell membrane of the parasite and interfering with its metabolic activities, causing cell death. It halts the growth and survival of the parasite, making miltefosine an effective oral treatment for visceral leishmaniasis or kala azar.

Who Are The Major Stakeholders Operating In The Visceral Leishmaniasis Market?

Major companies operating in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, TLC.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

How Do Regional Dynamics Influence The Visceral Leishmaniasis Market Performance?

North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp

Browse Through More Reports Similar to the Global Visceral Leishmaniasis Market 2025, By The Business Research Company

Visceral Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report

Liver Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Gene Delivery Technologies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model